Loading
NASDAQHealthcareBiotechnology
Latest quote
$67.51
+$1.29 · +1.95%
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
Latest quote
$67.51
+$1.29 · +1.95%
After-hours
$67.32
−$0.19 · -0.28%
Sep 10, 5:08 PM ET
Regular session · ET · Market data may be delayed.
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
Day range
Current $67.51
52-week range
Current $67.51
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
78
Undervalued
Sentiment
58
Mixed
Risk
37
Moderate Risk
Momentum
62
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
Day range
Current $67.51
52-week range
Current $67.51
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 490.73M USD | 233.18M USD | 145.24M USD | 109.46M USD | 131.84M USD |
| Cost of goods sold | 10.34M USD | 7.74M USD | 11.45M USD | 4.42M USD | 3.82M USD |
| Gross profit | 480.39M USD | 225.43M USD | 133.79M USD | 105.04M USD | 128.02M USD |
| Research and development | 206.01M USD | 282.7M USD | 244.99M USD | 227.33M USD | 201.16M USD |
| Selling, general, and administrative | 337.2M USD | 264.12M USD | 265.54M USD | 197.52M USD | 126.28M USD |
| Operating expenses | 543.21M USD | 549.26M USD | 521.93M USD | 424.85M USD | 327.44M USD |
| Interest income | 12.72M USD | 17.82M USD | 21.77M USD | 6.28M USD | 1.99M USD |
| Interest expense | 10.75M USD | 11.18M USD | 11.33M USD | 11.01M USD | 19.68M USD |
| Depreciation and amortization | 60.74M USD | 43.56M USD | 38.53M USD | 20.72M USD | 12.75M USD |
| Operating income | −62.82M USD | −323.83M USD | −388.14M USD | −319.81M USD | −199.43M USD |
| Net income | −25.55M USD | −321.55M USD | −111.4M USD | −278.48M USD | −180.09M USD |
Company facts updated Sep 10, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI165.33M0.01%2.3T USD0.03%$373.24-0.62%
State Street SPDR S&P Biotech ETFXBI152.75M1.35%11.33B USD0.35%$156.82-1.61%
iShares Russell 2000 ETFIWM150.42M0.19%80.51B USD0.19%$287.7-1.01%
Vanguard Extended Market ETFVXF59.88M0.06%93.7B USD0.05%$236.16-1.05%
iShares Russell 2000 Growth ETFIWO55.56M0.38%14.7B USD0.24%$365.67-1.42%
iShares Biotechnology ETFIBB45.65M0.44%10.73B USD0.44%$202.64-1.39%
Schwab U.S. Small-Cap ETFSCHA29.43M0.13%22.62B USD0.03%$33.65-1.32%
Vanguard Russell 2000 ETFVTWO28.04M0.16%17.4B USD0.06%$116.34-1.00%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAVanguard Russell 2000 ETFVTWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
